Moody Aldrich Partners LLC Raises Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Moody Aldrich Partners LLC boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 142.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 163,483 shares of the company's stock after purchasing an additional 96,068 shares during the quarter. Protagonist Therapeutics comprises 1.7% of Moody Aldrich Partners LLC's holdings, making the stock its 12th largest holding. Moody Aldrich Partners LLC owned 0.27% of Protagonist Therapeutics worth $7,906,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Farallon Capital Management LLC boosted its holdings in shares of Protagonist Therapeutics by 1.2% in the 4th quarter. Farallon Capital Management LLC now owns 5,930,006 shares of the company's stock valued at $228,898,000 after buying an additional 69,000 shares in the last quarter. RTW Investments LP boosted its holdings in shares of Protagonist Therapeutics by 1.3% in the 4th quarter. RTW Investments LP now owns 5,498,545 shares of the company's stock valued at $212,244,000 after buying an additional 72,433 shares in the last quarter. BVF Inc. IL boosted its stake in Protagonist Therapeutics by 2.7% in the fourth quarter. BVF Inc. IL now owns 1,900,015 shares of the company's stock valued at $73,341,000 after acquiring an additional 49,848 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Protagonist Therapeutics by 6.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,392,652 shares of the company's stock valued at $53,758,000 after acquiring an additional 83,185 shares in the last quarter. Finally, Deep Track Capital LP acquired a new stake in Protagonist Therapeutics in the fourth quarter valued at approximately $38,600,000. Institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Trading Up 1.0%

Protagonist Therapeutics stock traded up $0.51 during mid-day trading on Friday, hitting $51.20. The company had a trading volume of 339,485 shares, compared to its average volume of 843,939. Protagonist Therapeutics, Inc. has a 12-month low of $32.50 and a 12-month high of $60.60. The company's fifty day moving average is $49.40 and its 200-day moving average is $44.66. The company has a market capitalization of $3.17 billion, a price-to-earnings ratio of 68.27 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.31. Protagonist Therapeutics had a net margin of 27.04% and a return on equity of 9.22%. The firm had revenue of $28.32 million for the quarter, compared to the consensus estimate of $30.44 million. As a group, sell-side analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PTGX has been the subject of a number of recent analyst reports. Wedbush reissued an "outperform" rating and issued a $70.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, March 28th. BMO Capital Markets boosted their price target on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. Citigroup started coverage on Protagonist Therapeutics in a research note on Tuesday, June 17th. They set a "buy" rating and a $72.00 price target on the stock. Truist Financial boosted their target price on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a research report on Tuesday, March 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $66.10.

Insider Activity

In other Protagonist Therapeutics news, CFO Asif Ali sold 1,756 shares of the stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $46.00, for a total transaction of $80,776.00. Following the transaction, the chief financial officer owned 61,065 shares in the company, valued at approximately $2,808,990. This represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Arturo Md Molina sold 10,000 shares of the stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $57.03, for a total value of $570,300.00. Following the transaction, the insider owned 83,892 shares in the company, valued at $4,784,360.76. This represents a 10.65% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.90% of the company's stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.